|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
101,390,000 |
Market
Cap: |
1.64(B) |
Last
Volume: |
668,805 |
Avg
Vol: |
666,996 |
52
Week Range: |
$12.32 - $16.78 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Innoviva is a company with a portfolio of royalties and other healthcare assets. Co.'s royalty portfolio contains respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA® and TRELEGY® ELLIPTA®. Co. is entitled to royalty payments made by GSK under its agreements that assigned to Theravance Respiratory Company, LLC (TRC), including TRELEGY® ELLIPTA® and any other product or combination of products that may be discovered or developed in the future under the Long-Acting Beta2 Agonist Collaboration Agreement and the Strategic Alliance Agreement with GSK, which have been assigned to TRC other than RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) ![](../../images/information.jpg) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
664,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$8,468,005 |
Total People Bought |
0 |
0 |
0 |
2 |
Total Buy Transactions |
0 |
0 |
0 |
12 |
Total Shares Sold |
0 |
0 |
10,994 |
10,994 |
Total Sell Value |
$0 |
$0 |
$153,810 |
$153,810 |
Total People Sold |
0 |
0 |
1 |
1 |
Total Sell Transactions |
0 |
0 |
1 |
1 |
End Date |
2024-03-21 |
2023-12-19 |
2023-06-20 |
2022-06-20 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Gunderson Robert V Jr |
Director |
|
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
65,396 |
|
- |
|
Malkiel Burton G |
Director |
|
2010-04-27 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
18,000 |
|
- |
|
Waltrip William H |
Director |
|
2010-02-25 |
4 |
OE |
$8.53 |
$275,161 |
D/D |
32,258 |
44,258 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2010-02-25 |
4 |
B |
$10.33 |
$6,993 |
D/D |
677 |
158,618 |
2.74 |
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2010-02-24 |
4 |
B |
$10.48 |
$126,022 |
D/D |
12,025 |
157,941 |
2.74 |
- |
|
Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
|
2010-02-20 |
4 |
D |
$10.22 |
$11,886 |
D/D |
(1,163) |
250,664 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2010-02-20 |
4 |
D |
$10.22 |
$4,098 |
D/D |
(401) |
36,146 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2010-02-20 |
4 |
D |
$10.22 |
$16,935 |
D/D |
(1,657) |
113,825 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2010-02-20 |
4 |
D |
$10.22 |
$13,644 |
D/D |
(1,335) |
145,916 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2010-02-20 |
4 |
D |
$10.22 |
$13,470 |
D/D |
(1,318) |
125,326 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2010-02-20 |
4 |
D |
$10.22 |
$24,661 |
D/D |
(2,413) |
166,627 |
|
- |
|
Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
251,827 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
126,644 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
36,547 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
115,482 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
169,040 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2010-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
147,251 |
|
- |
|
Vagelos P Roy |
Director |
|
2009-12-23 |
4 |
OE |
$8.53 |
$1,706,000 |
D/D |
200,000 |
404,802 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2009-12-16 |
4 |
S |
$13.01 |
$25,448 |
D/D |
(1,956) |
11,547 |
|
- |
|
Mammen Mathai |
SVP, Research & Early Clin Dev |
|
2009-11-20 |
4 |
D |
$14.04 |
$15,444 |
D/D |
(1,100) |
101,644 |
|
- |
|
Winningham Rick E |
Chief Executive Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$33,191 |
D/D |
(2,364) |
114,040 |
|
- |
|
Shafer Bradford J |
Sr VP, Gen. Counsel, Secretary |
|
2009-11-20 |
4 |
D |
$14.04 |
$13,633 |
D/D |
(971) |
226,827 |
|
- |
|
Brinkley David L |
Head of Business Dev. |
|
2009-11-20 |
4 |
D |
$14.04 |
$9,884 |
D/D |
(704) |
13,503 |
|
- |
|
Blum Leonard M |
Sr VP, Chief Comm. Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$15,641 |
D/D |
(1,114) |
122,251 |
|
- |
|
Aguiar Michael W |
Sr VP, Chief Financial Officer |
|
2009-11-20 |
4 |
D |
$14.04 |
$19,403 |
D/D |
(1,382) |
90,482 |
|
- |
|
704 Records found
|
|
Page 23 of 29 |
|
|